The purpose of the study is to evaluate whether the use of a once-daily tacrolimus-dose regimen (Advagraf®), based on anti-thymocyte globuline (Thymoglobulin®) induction, mycophenolate mofetil (MMF) and corticosteroids, reduces the cumulative incidence of CLAD after de novo lung transplantation at 36 months, in comparison with a twice-daily cyclosporin-based protocol, otherwise identical between groups.
Study population is 242 male or female lung recipients 18-70 years of age undergoing primary double (including size reduction) lung transplantation (LTx), and who are willing and capable of giving written informed consent for study participation and anticipated to be able to participate in the study for 36 months.
